OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone267-364-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.07 million
Profitability
Miscellaneous
Employees102
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
OptiNose (NASDAQ:OPTN) Frequently Asked Questions
What is OptiNose's stock symbol?
OptiNose trades on the NASDAQ under the ticker symbol "OPTN."
How were OptiNose's earnings last quarter?
OptiNose Inc (NASDAQ:OPTN) released its quarterly earnings results on Monday, August, 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.09. The firm had revenue of $6.68 million for the quarter, compared to the consensus estimate of $7.74 million. OptiNose had a negative return on equity of 102.10% and a negative net margin of 670.20%. View OptiNose's Earnings History.
When is OptiNose's next earnings date?
What price target have analysts set for OPTN?
4 Wall Street analysts have issued 12 month target prices for OptiNose's stock. Their predictions range from $20.00 to $29.00. On average, they anticipate OptiNose's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 267.1% from the stock's current price. View Analyst Price Targets for OptiNose.
What is the consensus analysts' recommendation for OptiNose?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose.
What are Wall Street analysts saying about OptiNose stock?
Here are some recent quotes from research analysts about OptiNose stock:
- 1. According to Zacks Investment Research, "OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. " (7/11/2019)
- 2. Cantor Fitzgerald analysts commented, ". Post 1Q19, we are reiterating our OW rating and $27 12- month PT for OPTN. Despite a lumpy Xhance initial launch, we believe we are beginning to see Xhance gain traction, which supports our confidence in the peak sales potential of the product. In 2019, we believe the increased access, better affordability, the sales force expansion and increased awareness of the good efficacy data should continue to drive script growth throughout the year, and beyond. OPTN has evolved aspects of its launch strategy, which we view as positive and believe are beginning to pay dividends. We continue to take a conservative approach to Xhance revenue in 2019 while the updated launch strategy is fully implemented." (5/9/2019)
Has OptiNose been receiving favorable news coverage?
News articles about OPTN stock have been trending negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. OptiNose earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for OptiNose.
Are investors shorting OptiNose?
OptiNose saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 9,618,200 shares, an increase of 5.0% from the July 31st total of 9,159,600 shares. Based on an average trading volume of 232,100 shares, the days-to-cover ratio is currently 41.4 days. Approximately 60.6% of the company's stock are sold short. View OptiNose's Current Options Chain.
Who are some of OptiNose's key competitors?
Some companies that are related to OptiNose include Radius Health (RDUS), Zymeworks (ZYME), Innoviva (INVA), ArQule (ARQL), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Theravance Biopharma (TBPH), Dicerna Pharmaceuticals (DRNA), Amphastar Pharmaceuticals (AMPH), TherapeuticsMD (TXMD), AnaptysBio (ANAB), Epizyme (EPZM), Odonate Therapeutics (ODT), Phibro Animal Health (PAHC) and Y-mAbs Therapeutics (YMAB).
What other stocks do shareholders of OptiNose own?
Who are OptiNose's key executives?
OptiNose's management team includes the folowing people:
- Mr. Peter K. Miller, CEO & Director (Age 58)
- Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 54)
- Mr. Keith Alan Goldan, Chief Financial Officer (Age 48)
- Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 43)
- Mr. Thomas E. Gibbs, Exec. VP & Chief Commercial Officer (Age 47)
When did OptiNose IPO?
(OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.
How do I buy shares of OptiNose?
Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OptiNose's stock price today?
One share of OPTN stock can currently be purchased for approximately $6.81.
How big of a company is OptiNose?
OptiNose has a market capitalization of $282.18 million and generates $7.07 million in revenue each year. The company earns $-106,660,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. OptiNose employs 102 workers across the globe.View Additional Information About OptiNose.
What is OptiNose's official website?
How can I contact OptiNose?
OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]
MarketBeat Community Rating for OptiNose (NASDAQ OPTN)
MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
